Full Press Release Details
Sinovac Holds 2012 Annual General Meeting
BEIJING, Aug. 23, 2012 /PRNewswire-Asia/ -- Sinovac Biotech
Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it held its 2012 Annual General Meeting
of Shareholders on Wednesday, August 22, 2012 at 9:00 a.m. Beijing Time. The required quorum, a majority of the common shares outstanding,
was voted by proxy. The meeting was held concurrently at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC and at No. 6 Temple
Street, St. John's, Antigua.
During the meeting, the four proposals that required the affirmative
vote of a majority of the shares cast were approved as follows: all of the directors were re-elected; the audited consolidated
financial statements for financial year ended December 31, 2011 were approved, the selection of Ernst & Young as independent
auditor was confirmed, and the 2012 Share Incentive Plan was approved. Proposal No. 5 relating to amending Sections 7.5 of the
Company's by-laws, which requires the affirmative vote of a majority of common shares outstanding, was not approved.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company
that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious
diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu) and H1N1 influenza (swine flu), as
well as animal rabies vaccine for canines. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1
influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling
program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac
is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot and mouth disease), pneumococcal
conjugate, pneumococcal polysaccharides, mumps and rubella. Sinovac sells its vaccines mainly in China and exports selected
vaccines to Mongolia, Nepal, and the Philippines.
Safe Harbor Statement
This announcement contains forward-looking statements. These
statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995.
These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in this press release contain forward-looking statements.
Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to
differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel: +86-10-8279-9871/9659
Fax: +86-10-6296-6910
Email: ir@sinovac.com
Stephanie Carrington
Tel: +1-646-536-7017
Email: scarrington@theruthgroup.com
Tel: +1-646-536-7013
Email: vaguiar@theruthgroup.com